Accelerate Diagnostics, Inc (AXDX): Jack W Schuler , director 10% owner of Accelerate Diagnostics, Inc purchased 10,000 shares on May 17, 2016. The Insider buying transaction was reported by the company on May 18, 2016 to the Securities and Exchange Commission. The shares were purchased at $11.45 per share for a total value of $114,500.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 17, 2016, Jack W Schuler (director 10% owner) purchased 11,511 shares at $11.91 per share price.On Feb 10, 2016, Matthew Strobeck (director) purchased 20,000 shares at $11.52 per share price.Also, On Feb 9, 2016, John Patience (director 10% owner) purchased 50,000 shares at $11.39 per share price.On Feb 9, 2016, Larry N Feinberg (10% owner) sold 600,000 shares at $11.86 per share price.
Shares of Accelerate Diagnostics Inc (AXDX) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -0.08 points or -0.70% at $11.27 with 1,95,621 shares getting traded. Post opening the session at $11.28, the shares hit an intraday low of $10.91 and an intraday high of $11.52 and the price vacillated in this range throughout the day. The company has a market cap of $577,227 M and the number of outstanding shares has been calculated to be 51,21,80,00,000 shares. The 52-week high of Accelerate Diagnostics Inc is $31.29 and the 52-week low is $10.2901.
Company has been under the radar of several Street Analysts.Accelerate Diagnostics Inc is Initiated by JP Morgan to Overweight and the brokerage firm has set the Price Target at $17. The Rating was issued on Mar 24, 2016.
Accelerate Diagnostics Inc. is an in-vitro diagnostics company providing solutions to improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. The Company is focused on reducing the failure rate of initial antibiotic drug therapy by shortening lab turnaround time to approximately five hours rather than the two to three days required to deliver identification and susceptibility results. It has developed a diagnostic platform the Accelerate ID/AST System (the ID/AST System) intended for the rapid diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST) which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. Accelerate Diagnostics UK Limited is a subsidiary of the Company.